Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status

BACKGROUNDS: Ovarian cancer (OC) is still the leading aggressive and lethal disease of gynecological cancers, and platinum-based regimes are the standard treatments. However, nearly 20%–30% of patients with OC are initial platinum resistant (IPR), and there is a lack of valid tools to predict whethe...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yongmei, Nie, Yufei, Guo, Hongyan, Guo, Hua, Ha, Chunfang, Li, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971787/
https://www.ncbi.nlm.nih.gov/pubmed/35372049
http://dx.doi.org/10.3389/fonc.2022.847085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971787/
https://www.ncbi.nlm.nih.gov/pubmed/35372049
http://dx.doi.org/10.3389/fonc.2022.847085

Ejemplares similares